Published Date: 17 Feb 2023
BACKGROUND: NSCLC is the most common and important cause of cancer worldwide. Assessment: The patient...
Read Full NewsResidual Asthma Exacerbations on Biologics Vary by Mechanism
Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.
Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.
Elizabeth Spencer, MD, discusses new data from 3 birth cohorts linking PFAS metabolites tied to maternal IBD to elevated calprotectin in children.
Jordan Axelrad, MD, MPH, discusses first-line IBD therapy selection, sequencing after failure, treat-to-target monitoring, and evaluating new agents
A gastroenterologist explains why IBD symptoms don't always signal a flare, the biomarkers used to confirm inflammation, and counseling patients through Crohn's disease.
ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis
1.
Melanoma Patient on Immunotherapy Develops Severe Dermatitis
2.
AI Model Has Promise for Predicting Checkpoint Inhibitor Activity in NSCLC
3.
FDA Approves Novel Targeted Therapy for Rare Blood Cancer
4.
Talquetamab Regimens Boost Survival in Multiple Myeloma
5.
A Possible Novel CAR-T Treatment for High-Risk R/R Follicular Lymphoma May Be Liso-Cel.
1.
Risk Assessment of Reduced Hematopoietic Reserve During Chronic Systemic Stress
2.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
3.
How is Digital Innovation Revolutionizing Gynecologic Oncology Treatment and Patient Engagement?
4.
Advanced Pathways in Oncology for Better Care
5.
Preventing Bleeding Complications During Anticoagulant Transitions
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
3.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
5.
Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation